Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 26% Improvement Relative Risk Aghajani et al. Favipiravir for COVID-19 LATE Is late treatment with favipiravir beneficial for COVID-19? Retrospective 991 patients in Iran Lower mortality with favipiravir (not stat. sig., p=0.28) Aghajani et al., J. Medical Virology, doi:10.1002/jmv.27053 Favors favipiravir Favors control

Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19

Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053
Aghajani et al., Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe.., Journal of Medical Virology, doi:10.1002/jmv.27053
Apr 2021   Source   PDF  
  All Studies   Meta
Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
This study includes remdesivir, favipiravir, and HCQ.
risk of death, 26.1% lower, HR 0.74, p = 0.28, treatment 40, control 951, univariate Cox proportional regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aghajani et al., 29 Apr 2021, retrospective, Iran, peer-reviewed, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Decreased in‐hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID‐19
Mohammad Haji Aghajani, Omid Moradi, Hossein Amini, Hamed Azhdari Tehrani, Elham Pourheidar, Mohammad M Rabiei, Mohammad Sistanizad
Journal of Medical Virology, doi:10.1002/jmv.27053
Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID-19) are related to the higher mortality rate. Because of limited data on the antiplatelet effect, we aimed to evaluate the impact of aspirin add-on therapy on the outcome of the patients hospitalized due to severe COVID-19. In this cohort study, patients with a confirmed diagnosis of severe COVID-19 admitted to Imam Hossein Medical
The main limitations of our study were the retrospective pattern of the study and lack of data about the probable adverse effect of aspirin, such as bleeding components. In conclusion, based on the result of our study, in patients who received aspirin, a relevant underlying condition such as hypertension, diabetes, and coronary artery disease was more prevalent. These patients had a more severe course of the disease and a longer duration of hospitalization. By adjustment of the effect of underlying conditions and confounding factors, aspirin use in severe hospitalized COVID-19 patients is independently associated with a 25% decrease in mortality rate. So, by considering all the probable described mechanisms and the results of other studies in this regard, we recommend using aspirin during the hospital stay for all patients with the diagnosis of severe COVID-19. ACKNOWLEDGMENT This study was supported via the Deputy of research and technology, Shahid Beheshti University of Medical Sciences, Iran. No specific grants from funding agencies, commercial, and non-profit sectors were received. CONFLICT OF INTERESTS The authors declare that there are no conflicts of interest. AUTHOR CONTRIBUTIONS
Abou-Ismail, Diamond, Kapoor, Arafah, Nayak, The hypercoagulable state in COVID-19: incidence, pathophysiology, and management, Thromb Res, doi:10.1016/j.thromres.2020.06.029
Aghajani, Moradi, Amini, Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19, J Med Virol
Barrett, Moore, Yaffe, Moore, ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment, J Thromb Haemost, doi:10.1111/jth.14860
Carfora, Spiniello, Ricciolino, Anticoagulant treatment in COVID-19: a narrative review, J Thromb Thrombolysis, doi:10.1007/s11239-020-02242-0
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and inhospital mortality in hospitalized patients with COVID-19
Cicci, Iyer, Clarke, Mazzella, Aspirin for the primary prevention of cardiovascular disease: a review of the literature and considerations for clinical practice, Cardiol Rev, doi:10.1097/CRD.0000000000000297
Godino, Scotti, Maugeri, Antithrombotic therapy in patients with COVID-19?-Rationale and evidence, Int J Cardiol, doi:10.1016/j.ijcard.2020.09.064
Levi, Thachil, Iba, Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Hematol, doi:10.1016/S2352-3026(20)30145-9
Mcfadyen, Stevens, Peter, The emerging threat of (Micro) thrombosis in COVID-19 and its therapeutic implications, Circ Res, doi:10.1161/CIRCRESAHA.120.317447
Mulcahy, Ghulam-Smith, Mamidi, Oropharyngeal hemorrhage in patients with COVID-19: a multi-institutional case series, Am J Otolaryngol, doi:10.1016/j.amjoto.2020.102691
Porfidia, Valeriani, Pola, Porreca, Rutjes et al., Venous thromboembolism in patients with COVID-19: systematic review and meta-analysis, Thromb Res, doi:10.1016/j.thromres.2020.08.020
Rapkiewicz, Mai, Carsons, Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100434
Sivaloganathan, Ladikou, Chevassut, COVID-19 mortality in patients on anticoagulants and antiplatelet agents, Br J Haematol, doi:10.1111/bjh.16968
Vasanthakumar, Beta-adrenergic blockers as a potential treatment for COVID-19 patients, BioEssays, doi:10.1002/bies.202000094
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Yuan, Chen, Li, Chen, Wang et al., Mortality and prehospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease, J Cell Mol Med, doi:10.1111/jcmm.16198
Zhang, Zhu, Cai, Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res, doi:10.1161/CIRCRESAHA.120.317134
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop